HCA
GILD icon

Heck Capital Advisors’s Gilead Sciences GILD Stock Holding History

Heck Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-76
Closed -$7.02K – 458
2024
Q4 		$7.02K Buy
+76
New +$6.84K ﹤0.01% 556
2017
Q1 		– Sell
-1,093
Closed -$78.3K – 76
2016
Q4 		$78.3K Buy
+1,093
New +$81.2K 0.06% 61

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Heck Capital Advisors's GILD Position: Q1 2025 in Review

Heck Capital Advisors sold out of Gilead Sciences (GILD) in Q1 2025, closing a stake of 76 shares — an estimated $7.02K sold.

Heck Capital Advisors first reported a position in GILD in Q4 2016 and held it in 2 quarters. The position peaked at $78.3K in Q4 2016. 2,019 funds tracked by Wall St. Rank hold GILD as of Q1 2025.

  • Heck Capital Advisors reported no remaining Gilead Sciences position as of Q1 2025 after selling out during the quarter.
  • Heck Capital Advisors sold 76 Gilead Sciences shares in Q1 2025, an estimated $7.02K.
  • Heck Capital Advisors first reported a position in Gilead Sciences in Q4 2016 and held it in 2 quarters.
  • Heck Capital Advisors's Gilead Sciences position peaked at $78.3K in Q4 2016.
  • 2,019 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2025.

Based on Heck Capital Advisors's 13F filing for Q1 2025, filed 13 May 2025.